Christopher Wehner, managing director of BMW Group Asia, explains how electric cars such as the BMW
SINGAPORE (May 18): Hyphens Pharma International, the latest healthcare stock making it Catalist debut this morning, opened at 30 cents, 15.4% higher than its IPO price of 26 cents.
As at 11.59am, the stock was trading at 28.5 cents with some 17.4 million shares changing hands.
Hyphens Pharma has three income streams. One is the specialty pharmaceutical segment involved in the selling and marketing of specialty pharmaceutical products from brands such as Guerbet and Bausch+Lomb.
The other is the development and sale of its own range of dermatological products and health supplements under its proprietary brands segment, under the “Ceradan”, “TDF” and “Ocean Health” labels.
Yet another is the medical hypermart and digital business segment which sells medicine on a wholesale basis to clinics. It also has an e-commerce platform distributing these drugs to clinics in Singapore.
“It is not easy for an SME [small and medium enterprise] to build different streams of income. We are very fortunate to have three,” Lim See Wah, Hyphens Pharma’s chairman and CEO, tells The Edge Singapore. “[And] all the three segments are growing, although at a slightly different pace.”
To find out more about Hyphens Pharma and its business, get your copy of The Edge Singapore (Issue No. 831, week of May 21) which is on sale now.